Kopran Limited (BOM:524280)
199.65
+9.50 (5.00%)
At close: Aug 17, 2026
Kopran Revenue
Kopran had revenue of 1.54B INR in the quarter ending June 30, 2026, with 13.89% growth. This brings the company's revenue in the last twelve months to 7.00B, up 11.96% year-over-year. In the fiscal year ending March 31, 2026, Kopran had annual revenue of 6.81B with 8.23% growth.
Revenue (ttm)
7.00B
Revenue Growth
+11.96%
P/S Ratio
1.38
Revenue / Employee
6.06M
Employees
1,156
Market Cap
9.64B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.81B | 518.19M | 8.23% |
| Mar 31, 2025 | 6.30B | 150.13M | 2.44% |
| Mar 31, 2024 | 6.15B | 636.05M | 11.54% |
| Mar 31, 2023 | 5.51B | 734.66M | 15.38% |
| Mar 31, 2022 | 4.78B | -142.93M | -2.91% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anuh Pharma | 7.79B |
| Sudarshan Pharma Industries | 7.32B |
| Lincoln Pharmaceuticals | 7.03B |
| Wanbury | 6.53B |
| Amrutanjan Health Care | 5.11B |
| Fermenta Biotech | 5.11B |
| Syncom Formulations (India) | 4.89B |
| Hexagon Nutrition | 4.15B |